tetano
Editor, Senior Moderator
Front Med
. 2022 Feb 3.
doi: 10.1007/s11684-021-0914-x. Online ahead of print.
Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults
Yuntao Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Yunkai Yang[SUP] #[/SUP][SUP] 1 [/SUP], Niu Qiao[SUP] #[/SUP][SUP] 2 [/SUP], Xuewei Wang[SUP] 1 [/SUP], Ling Ding[SUP] 3 [/SUP], Xiujuan Zhu[SUP] 3 [/SUP], Yu Liang[SUP] 4 [/SUP], Zibo Han[SUP] 4 [/SUP], Feng Liu[SUP] 2 [/SUP], Xinxin Zhang[SUP] 5 [/SUP], Xiaoming Yang[SUP] 6 [/SUP]
Affiliations
Abstract
Inducing durable and effective immunity against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) via vaccination is essential to combat the current pandemic of coronavirus disease 2019 (COVID-19). It has been noticed that the strength of anti-COVID-19 vaccination-induced immunity fades over time, which calls for an additional vaccination regime, as known as booster immunization, to restore immunity among previously vaccinated populations. Here we report a pilot open-label trial of a third dose of BBIBP-CorV, an inactivated SARS-CoV-2 vaccine (Vero cell), on 136 participants aged between 18 to 63 years. Safety and immunogenicity in terms of neutralizing antibody titers and cytokine/chemokine responses were analyzed as the main endpoint until day 28. While systemic reactogenicity was either absent or mild, SARS-CoV-2-specific neutralizing antibody titers rapidly arose in all participants within 4 weeks, surpassing the peak antibody titers elicited by the initial two-dose immunization regime. Broad increases of cellular immunity-associated cytokines and chemokines were also detected in the majority of participants after the third vaccination. Furthermore, in an exploratory study, a newly developed recombinant protein vaccine, NVSI-06-08 (CHO Cells), was found to be safe and even more effective than BBIBP-CorV in eliciting humoral immune responses in BBIBP-CorV-primed individuals. Together, these results indicate that a third immunization schedule with either homologous or heterologous vaccine showed favorable safety profiles and restored potent SARS-CoV-2-specific immunity, providing support for further trials of booster vaccination in larger populations.
Keywords: COVID-19; SARS-CoV-2; booster immunization; immunization; vaccine.
. 2022 Feb 3.
doi: 10.1007/s11684-021-0914-x. Online ahead of print.
Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults
Yuntao Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Yunkai Yang[SUP] #[/SUP][SUP] 1 [/SUP], Niu Qiao[SUP] #[/SUP][SUP] 2 [/SUP], Xuewei Wang[SUP] 1 [/SUP], Ling Ding[SUP] 3 [/SUP], Xiujuan Zhu[SUP] 3 [/SUP], Yu Liang[SUP] 4 [/SUP], Zibo Han[SUP] 4 [/SUP], Feng Liu[SUP] 2 [/SUP], Xinxin Zhang[SUP] 5 [/SUP], Xiaoming Yang[SUP] 6 [/SUP]
Affiliations
- PMID: 35122211
- DOI: 10.1007/s11684-021-0914-x
Abstract
Inducing durable and effective immunity against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) via vaccination is essential to combat the current pandemic of coronavirus disease 2019 (COVID-19). It has been noticed that the strength of anti-COVID-19 vaccination-induced immunity fades over time, which calls for an additional vaccination regime, as known as booster immunization, to restore immunity among previously vaccinated populations. Here we report a pilot open-label trial of a third dose of BBIBP-CorV, an inactivated SARS-CoV-2 vaccine (Vero cell), on 136 participants aged between 18 to 63 years. Safety and immunogenicity in terms of neutralizing antibody titers and cytokine/chemokine responses were analyzed as the main endpoint until day 28. While systemic reactogenicity was either absent or mild, SARS-CoV-2-specific neutralizing antibody titers rapidly arose in all participants within 4 weeks, surpassing the peak antibody titers elicited by the initial two-dose immunization regime. Broad increases of cellular immunity-associated cytokines and chemokines were also detected in the majority of participants after the third vaccination. Furthermore, in an exploratory study, a newly developed recombinant protein vaccine, NVSI-06-08 (CHO Cells), was found to be safe and even more effective than BBIBP-CorV in eliciting humoral immune responses in BBIBP-CorV-primed individuals. Together, these results indicate that a third immunization schedule with either homologous or heterologous vaccine showed favorable safety profiles and restored potent SARS-CoV-2-specific immunity, providing support for further trials of booster vaccination in larger populations.
Keywords: COVID-19; SARS-CoV-2; booster immunization; immunization; vaccine.